Source: CureToday articles
The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects.
Recent Content
- Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
- IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
- Combination induces durable responses in advanced multiple myeloma
- Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
- Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
- Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
- Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
- Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
- A Year of Resilience: Looking Back After a Myeloma Diagnosis
- Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma